162368-02-7

Basic information

• Product Name: 1-(1-acetyl-4-piperidinyl)-2-bromoEthanone
• Synonyms: 1-(1-acetyl-4-piperidinyl)-2-bromoEthanone
• CAS NO: 162368-02-7
• Molecular Formula: C₉H₁₄BrNO₂
• Molecular Weight: 248.11696
• Mol File: 162368-02-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(1-acetyl-4-piperidinyl)-2-bromoEthanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1-acetyl-4-piperidinyl)-2-bromoEthanone(162368-02-7)
• EPA Substance Registry System: 1-(1-acetyl-4-piperidinyl)-2-bromoEthanone(162368-02-7)

Safety Data

• Hazardous Substances Data: 162368-02-7(Hazardous Substances Data)

Usage

Chemical structure

Contains a piperidine ring, acetyl group, and a bromine atom.

Type of compound

Synthetic compound with potential biological activities.

Acetyl group

Suggests involvement in acetylation reactions in biological processes.

Bromine atom

Adds reactivity and potential for forming covalent bonds with other molecules.

Chemical modifications

Useful for chemical modifications and drug development due to bromine atom.

Pharmaceutical applications

Piperidine ring is a common structural motif in many pharmaceutical compounds.

Potential applications

May have potential applications in the development of new drugs.

Medicinal chemistry

Has potential uses in medicinal chemistry.

Building block

Can be used as a building block for chemical synthesis.

Upstream product

• 162368-01-6 N-acetyl-1-(piperidin-4-yl)ethanone 
• 498-94-2 isonipecotic acid 
• 25503-90-6 1-acetyl-piperidine-4-carboxylic acid 
• 213886-98-7 1-acetyl-N-methoxy-N-methylpiperidine-4-carboxamide 

Downstream Products

• 953130-88-6 1-(4-(2-(5-bromo-3-phenoxypyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 953044-73-0 1-(4-(2-(5-(3-methylthieno[3,2-b]pyridin-7-ylthio)-3-phenoxypyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 953130-97-7 1-(4-(2-(3-phenoxy-5-(thieno[3,2-b]pyridin-7-ylthio)pyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 953044-77-4 1-(4-(2-(3-phenoxy-5-(thieno[2,3-d]pyrimidin-4-ylthio)pyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 1065604-63-8 1-(4-(2-(5-(3-hydroxypropylthio)-3-phenoxypyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 953046-49-6 methyl 3-(6-(4-(1-acetylpiperidin-4-yl)thiazol-2-ylamino)-5-phenoxypyridin-3-ylthio)propanoate 

Relevant articles and documents

NOVEL GPR119 AGONIST COMPOUNDS

The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.

INHIBITORS OF SPHINGOSINE KINASE

The present invention relates to compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12,

2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS

Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS

Provided are compounds having the Formula (I) or salts thereof, wherein: L is O, S, SO, SO2, CHOH, C(O), or CH2; D2 is CR12 or N; R2 is aryl, heteroaryl, saturated or partially unsaturated cycloalkyl, or saturated or partially unsaturated heterocyclyl (optionally substituted with oxo), wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl are monocyclic or bicyclic and are further optionally substituted with one or more groups independently selected from C1-C6 alkyl, F, Cl, Br, I, CF3, CN, OR6, C(=O)R6, C(=O)OR6, O(CH2)nC(=O)OR6, C(=O)NR6R7, NO2 and (1-6C alkyl)OR6; R3 is H, Br, OR6, SR6, C(O)OR6, C(O)NR6R7, C(O)R6, heteroaryl, or C1-C6 alkyl substituted with one or more groups independently selected from Vn-aryl, Vn-OR6, Vn- C(=O)OR6 and Vn-NR6R7; R11 is H or Cl; and R13 is N-(1 -6C alkanoyl)piperidin-4-yl; that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

GLUCOKINASE ACTIVATORS

Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase. (Formula I) wherein R2, L, Z, Y, G and R1 are as defined in the claims.